MedTrace Logo

Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan

NCT04268524 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 832

Last updated 2025-05-09

No results posted yet for this study

Summary

randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alternative treatment options to treat cutaneous leishmaniasis caused by L. tropica, in Pakistan compared to the standard of care.

Conditions

  • Old World Cutaneous Leishmaniasis

Interventions

COMBINATION_PRODUCT

drug: miltefosine with thermotherapy

see previous

Sponsors & Collaborators

  • Medecins Sans Frontieres, Netherlands

    lead OTHER

Principal Investigators

  • Koert Ritmeijer · Medecins Sans Frontieres, Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-07
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04268524 on ClinicalTrials.gov